Biologic Therapies in Refractory Nasal Polyposis

Abstract

Refractory nasal polyposis (NP) presents significant clinical challenges due to persistent symptoms, high recurrence rates, and limited response to conventional therapies. The advent of biologic therapies has introduced a paradigm shift in the management of difficult-to-treat cases, offering targeted intervention based on molecular mechanisms underlying chronic rhinosinusitis with nasal polyps (CRSwNP). This article provides a comprehensive review of the epidemiology, pathophysiology, risk factors, clinical features, and management of refractory NP, with a special focus on the role, efficacy, and safety of biologic agents. Recent advances are discussed alongside current guideline recommendations, aiming to equip clinicians with evidence-based strategies for optimal patient outcomes.

Introduction

Nasal polyposis, particularly in its refractory form, is a chronic inflammatory disorder of the sinonasal mucosa characterized by benign, edematous outgrowths that cause significant morbidity. Despite the use of intranasal corticosteroids, systemic steroids, and repeated endoscopic sinus surgeries, a subset of patients continues to experience persistent or recurrent symptoms, highlighting the need for innovative treatment modalities. Biologic therapies, targeting specific inflammatory pathways, have emerged as a promising option for patients unresponsive to standard interventions. This review synthesizes current knowledge and clinical advances in biologic management of refractory NP, providing insights relevant to otolaryngologists, allergists, and other healthcare professionals involved in respiratory and immunologic care.

Epidemiology / Disease Burden

Chronic rhinosinusitis with nasal polyps affects approximately 2–4% of the adult population worldwide, with higher prevalence in males and individuals over 40 years of age. Refractory NP, defined by persistent symptoms despite maximal medical therapy and/or multiple surgeries, constitutes a substantial subset with considerable impact on health-related quality of life. Patients frequently report anosmia, nasal obstruction, facial pressure, and recurrent infections, leading to sleep disturbances and impaired social functioning. The economic burden is marked by frequent healthcare utilization, absenteeism, and direct medical costs, underscoring the need for effective long-term management strategies.

Pathophysiology

The underlying pathophysiology of NP involves a complex interplay between genetic susceptibility, environmental triggers, and dysregulated mucosal immunity. In Western populations, the disease predominantly follows a type 2 (Th2) inflammatory endotype, characterized by elevated levels of interleukin (IL)-4, IL-5, and IL-13, eosinophilic infiltration, and increased IgE production. These molecular pathways drive tissue edema, glandular hyperplasia, and extracellular matrix remodeling, culminating in polyp formation. Other mechanisms, including neutrophilic inflammation and barrier dysfunction, may contribute in non-type 2 endotypes, indicating heterogeneity in disease expression and response to therapy.

Risk Factors

Several risk factors predispose individuals to refractory NP. These include comorbid asthma (especially severe or aspirin-exacerbated respiratory disease), atopy, nonsteroidal anti-inflammatory drug (NSAID) intolerance, smoking, and occupational exposures. Genetic polymorphisms affecting cytokine regulation and epithelial barrier function have also been implicated. A history of multiple prior sinus surgeries and corticosteroid dependence are markers for disease severity and refractoriness. Understanding these risk profiles is crucial for early identification and tailored management.

Clinical Features

Patients with NP typically present with chronic nasal obstruction, anterior/posterior rhinorrhea, facial pain or pressure, and hyposmia or anosmia. Endoscopic examination reveals bilateral, glistening, pale polyps arising from the middle meatus, often extending into the nasal cavity. In refractory cases, symptoms persist or recur rapidly after surgery or corticosteroid therapy, with a tendency toward large polyp burden, mucopurulent discharge, and comorbid lower airway disease. Quality of life is significantly compromised, warranting aggressive and sustained intervention.

Diagnosis

Diagnosis is based on clinical history, nasal endoscopy, and radiologic imaging. The European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) recommends confirmation of mucosal disease on computed tomography (CT), with the Lund-Mackay score often employed to quantify extent. Assessment of comorbidities, including asthma and aspirin sensitivity, is essential for comprehensive care. Emerging biomarkers, such as tissue or serum eosinophilia and total IgE, may help phenotype patients and predict response to targeted biologic therapy.

Treatment & Management

Standard management begins with intranasal corticosteroids, saline irrigations, and short courses of systemic steroids for acute exacerbations. Functional endoscopic sinus surgery (FESS) is indicated for those with persistent symptoms or obstruction. However, recurrence rates remain high, particularly among patients with type 2 inflammatory endotype and comorbid asthma. Long-term macrolides and leukotriene modifiers have been explored with variable benefit. Despite maximal conventional therapy, many patients remain symptomatic, necessitating alternative options such as biologics.

Recent Advances / Emerging Therapies

The introduction of biologic agents marks a significant advancement in the management of refractory NP. Dupilumab, a monoclonal antibody targeting the IL-4Rα receptor and inhibiting both IL-4 and IL-13 signaling, has demonstrated substantial reduction in polyp size, nasal congestion, and improvement in quality of life in pivotal phase 3 trials (SINUS-24 and SINUS-52). Mepolizumab and benralizumab, targeting IL-5 and its receptor respectively, reduce eosinophilic inflammation and have shown efficacy in reducing polyp burden and need for surgery, especially among patients with concomitant severe asthma. Omalizumab, an anti-IgE monoclonal antibody, is effective in patients with allergic sensitization and high IgE levels. These therapies are administered subcutaneously and have favorable safety profiles, though long-term data on sustained efficacy and optimal duration are evolving. The choice of biologic is increasingly informed by endotype-driven approaches and patient comorbidities.

Guideline Recommendations

Recent international guidelines, including EPOS 2020 and the American Academy of Otolaryngology–Head and Neck Surgery, advocate for biologic therapy in adults with severe, uncontrolled CRSwNP despite prior surgery and/or systemic corticosteroid therapy, particularly in the presence of type 2 inflammation and comorbid asthma. Biomarker-driven selection, careful monitoring for adverse events, and multidisciplinary care are emphasized. Biologics should be considered as adjuncts, not replacements, for optimized medical and surgical management, with periodic assessment of response and need for continued therapy.

Conclusion

Biologic therapies have revolutionized the treatment paradigm for refractory nasal polyposis, offering hope for patients unresponsive to conventional interventions. By targeting key drivers of type 2 inflammation, these agents provide durable symptomatic relief, reduce surgical interventions, and improve quality of life. Ongoing research will refine patient selection, duration of therapy, and integration with existing management strategies. Multidisciplinary, evidence-based approaches remain paramount in delivering optimal outcomes for this challenging patient population.